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Key Messages: 
What is already known about this subject? 
Rituximab is increasingly being used as a remission induction agent in ANCA associated 
vasculitis. 
What does this study add? 
This large prospective cohort provides further efficacy and safety data for the use of 
rituximab in patients specifically with relapsing disease. 
How might this impact on clinical practice? 
Rituximab in conjunction with glucocorticoids is now an established induction strategy in 
ANCA associated vasculitis. 
 
 
 
 
  
ABSTRACT 
Objectives: 
Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in 
ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled 
into the induction phase of the RITAZAREM trial. 
 
Methods: 
Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were 
prospectively enrolled and received remission-induction therapy with rituximab (4 x 375 
mg/m
2
) and a higher- or lower-dose glucocorticoid regimen, depending on physician choice: 
reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Patients in 
this cohort achieving remission were subsequently randomized to receive one of two 
regimens to prevent relapse. 
 
Results: 
188 patients were studied: 95/188 (51%) male, median age 59 years (range 19-89), prior 
disease duration 5.0 years (range 0.4-34.5).  149/188 (79%) had previously received 
cyclophosphamide and 67/188 (36%) rituximab. 119/188 (63%) of relapses had at least one 
major disease activity item, and 54/188 (29%) received the higher-dose glucocorticoid 
regimen.   
171/188 (90%) patients achieved remission by 4 months. Only six patients (3.2% of the study 
population) did not achieve disease control at month 4. Four patients died in the induction 
phase due to pneumonia (2), cerebrovascular accident (1), and active vasculitis (1). 41 severe 
adverse events occurred in 27 patients, including 13 severe infections.   
 
Conclusions: 
This large prospective cohort of patients with relapsing ANCA-associated vasculitis treated 
with rituximab in conjunction with glucocorticoids, demonstrated a high level of efficacy for 
the re-induction of remission in patients with AAV who have relapsed, with a similar safety 
profile to previous studies.   
  
INTRODUCTION 
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the major 
subgroups of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
These conditions are characterized by leucocyte infiltration of blood vessel walls, fibrinoid 
necrosis, and vascular damage, and are usually associated with the presence of circulating 
ANCA(1).  
Prior to the availability of effective treatment, AAV had a mortality of 93% within two years, 
primarily due to renal and respiratory failure(2). The introduction of glucocorticoids and 
cyclophosphamide, which became established treatment for this disease in the 1980s, 
markedly improved survival, inducing remission at one year in approximately 80% of 
patients. However, relapsing disease is common with over 50% of patients experiencing a 
relapse within five years, and the majority suffering treatment-related toxicity(3-5). 
B-lymphocytes have been implicated in the pathogenesis of AAV. Rituximab is a 
murine/human chimeric monoclonal antibody directed against the CD20 antigen found on the 
surface of B-lymphocytes, and results in B cell depletion. Rituximab was shown to be non-
inferior to cyclophosphamide for induction of remission in AAV, and superior to 
cyclophosphamide for the treatment of relapsing disease (6, 7). Rituximab became a licensed 
therapy for remission induction of AAV in 2011. 
Fixed-interval, repeat-dosing of rituximab was shown to be superior to azathioprine as a 
maintenance strategy following induction of remission cyclophosphamide in a trial of 117 
patients with predominantly newly-diagnosed AAV (8). The optimal strategy to maintain 
remission following induction of remission with rituximab, especially for treatment of 
relapse, is not clear. RITAZAREM was an international, randomized, controlled trial 
designed to assess whether rituximab is superior to azathioprine for the maintenance of 
remission following induction of remission with rituximab and glucocorticoids in patients 
with relapsing AAV. In this trial, fixed-interval, repeat doses of rituximab were compared to 
daily azathioprine for maintenance of remission.  
Since all patients received rituximab for induction of remission in the RITAZAREM trial, 
this is the largest reported prospective cohort of patients with relapsing AAV to receive 
treatment with rituximab for induction of remission.  . This first report outlines the efficacy 
and safety of rituximab with either higher or lower dose glucocorticoids for induction of 
remission in a large prospective cohort of patients with relapsing AAV. 
 
  
METHODS: 
The details of the RITAZAREM protocol have been previously published(9).  In summary, 
RITAZAREM trial has three phases:  
1) An induction phase (Months 0 to 4): eligible patients enrolled at time of disease 
relapse received rituximab (4 weekly doses of 375 mg/m
2
) and glucocorticoids;  
2) A maintenance phase (months 4 to 24): four months after enrolment, participants who 
achieved remission (defined as a Birmingham Vasculitis Activity Score for 
Wegener’s granulomatosis (BVAS/WG) ≤ 1 and prednisone/prednisolone dose ≤ 10 
mg/day) were randomized in 1:1 ratio to receive 1000 mg rituximab at four-monthly 
fixed intervals or daily azathioprine (2 mg/kg/day).   
3) A follow-up phase: clinical follow-up after completion of therapy with either 
rituximab or azathioprine (minimum of 12, maximum of 24 months). 
 
This paper reports on the first, induction phase of the trial, prior to randomisation. 
 
Participants: 
Participants were aged over 15 years and had a diagnosis of GPA or MPA according to 
Chapel Hill Consensus Conference definitions (10), and a current or historical positive test 
for PR3- or MPO-ANCA. All patients had disease relapse defined by one major or three 
minor disease activity items on the BVAS/WG and had previously achieved remission 
following at least 3 months of induction therapy, with a combination of glucocorticoids and 
an immunosuppressive agent (cyclophosphamide, rituximab, methotrexate, or mycophenolate 
mofetil). 
Key exclusion criteria included the receipt of any biological B-cell-depleting agents within 
the previous 6 months, alemtuzumab or anti-thymocyte globulin (ATG) within the previous 
12 months, or intravenously administered immunoglobulin (IVIg), plasma exchange, or anti-
TNF treatment within the previous 3 months. Patients with other multisystem autoimmune 
diseases, such as eosinophilic granulomatous with polyangiitis (eGPA), systemic lupus 
erythematosus (SLE), anti-glomerular basement membrane (GBM) disease or 
cryoglobulinaemic vasculitis, or history of malignancy within the past 5 years were also 
excluded.  
Participants were recruited from 29 centers in 7 countries. 
 
Interventions, Induction Therapy: 
 
Rituximab: Rituximab 375 mg/m
2
/week was administered in four doses. 
 
Glucocorticoids: Investigators chose from one of two glucocorticoid regimens taking into 
consideration disease severity and local prescribing practices. Schedule 1A had a 
glucocorticoid starting dose of 1 mg/kg/day (maximum 60 mg daily) and 1B a starting dose 
of 0.5 mg/kg/day (maximum 30mg daily), both tapering to 10 mg daily by month 4.  
Deviation from the protocol-specified tapering glucocorticoid regimen was defined as a 25% 
higher or lower glucocorticoid dose, averaged over 2 weeks. Patients could also receive a 
maximum cumulative dose of 3000 mg IV methylprednisolone, between 14 days prior to 
enrolment and 7 days after enrolment. 
 
Other treatments: Prophylaxis to prevent pneumocystis (carinii) jiroveci infection and/or to 
prevent osteoporosis were recommended according to local practice. Plasma exchange could 
be administered during the induction period following local practice. However, rituximab 
was not administered within 48 hours before a plasma exchange treatment. 
Assessments: Evaluations (including clinical, biochemical, and patient-reported outcomes) 
were performed at 0, 1.5, 3, and 4 months. 
Power calculation: Enrolment was set to be open until at least 160 patients were randomized 
at their month 4 visits. It was anticipated that 190 patients would be required in order to 
randomize 160 patients. Details of how the sample size was determined have been previously 
published(9)  
Definitions: Remission was defined as a BVAS/WG of 1 or less with a 
prednisone/prednisolone dose of 10mg/day or less by four months. 
Statistical methods: Continuous variables are expressed as medians and interquartile ranges. 
Categorical variables are presented as percentages and frequencies. A set of univariate 
logistic regression analyses to predict remission at month 4 for candidate factors was 
performed. Estimates of marginal odds ratios, with 95% confidence intervals and p-values are 
presented. The statistical comparisons were not formally powered or pre-specified in the 
protocol so these results must be interpreted with caution.  Data were analysed using R 
version 3.6.1.   
 
  
RESULTS: 
Baseline demographics: 
188 patients were enrolled into the trial. Patient disposition throughout the 4-month induction 
period is shown in the consort diagram (Figure 1) and baseline demographics in Table 1.  
95/188 (51%) patients were male, with a median age of 59 years (range 19-89) and prior 
disease duration of 5.0 years (range 0.4-34.5).  149/188 (79%) patients had previously 
received cyclophosphamide (median dose 9 grams (range 0.15-301) and 67/188 (36%) had 
received rituximab (median dose 3910 mg (range 1000-16000)). At enrolment, 60/188 (32%) 
patients were on an oral immunosuppressive agent: (35/188 (19%) azathioprine; 12/188 (6%) 
mycophenolate mofetil; and 13/188 (7%) methotrexate), each of which were stopped as per 
protocol.   137/188 (73%) had a history of a positive test for PR3-ANCA, and 51/188 (37%) 
for MPO-ANCA.  119/188 (63%) of relapses had at least one major disease activity item, and 
54/188 (29%) patients received the higher-dose glucocorticoid regimen.  The median 
BVAS/WG at enrolment was 5, (range 3-14).  Distribution of baseline disease manifestations 
included: ear, nose, and throat: 120/187 (64.2%) patients, renal: 88 (47.1%), and respiratory 
involvement: 69 (36.9%). 
The median number of body systems previously affected by vasculitis was 5 (range 0-10).  
Prior organ involvement included renal in 127/188 (67.6%) patients, lung in 115/188 (61.2%) 
patients, and ear nose and throat in 138/188 (73.4%) patients.  Hypertension was common, 
affecting 93/199 (49.5%) patients.  23/188 (12.2%) patients had diabetes mellitus at 
enrolment; 29/188 (15.4%) chronic lung disease and 20/188 (10.6%) had previously suffered 
from malignancy.  
 
Treatment exposure: 
The median total dose of rituximab in the induction phase was 2937 mg (range 1552-4320 
mg) and cumulative oral glucocorticoid exposure in the 4-month induction phase was 
3010 mg (2485-7875 mg) in the 1A higher dose induction regimen and 1960 mg (1715-3535 
mg) in the 1B lower dose induction regimen.  There was no difference in cumulative 
glucocorticoid exposure between patients that achieved and did not achieve remission 
(median dose 1960mg in both groups (1A range: 1715-3010; 1B range 1715-7875).  25% of 
patients deviated from the specified glucocorticoid tapering regimen at some point in the 
induction phase.   
 
Disease response: 
171/188 (90%) patients achieved remission at month 4 (Figure 2).  Of the 17 patients who 
did not achieve remission by month 4, 13 (76%) had PR3-ANCA positive disease, and 10 
(59%) had ear, nose, and throat involvement at baseline.  14/17 (82%) patients who did not 
achieve remission had severe (at least one major BVAS/WG item) disease, and 5/17 patients 
(29%) received the higher glucocorticoid dosing regimen.  7/17 (41.2%) non-responders had 
previously received rituximab, median cumulative dose of 4125mg (1000-8930), which was 
comparable to responders (60/171 (35.1%); cumulative dose 3910mg (1500-16000)).   At 
month 4, 3 patients had ongoing ENT disease activity; 3 had pulmonary manifestations; 2 had 
active renal disease, and 4 had other features of active disease (fatigue (2), pachymeningitis 
(1), headache (1)).  None of the following baseline variables were predictive of disease 
response: age, ANCA type at enrolment, , glucocorticoid induction regimen, presence of ear, 
nose, and throat or renal involvement (Supplementary Table 1), although it is notable non 
severe disease was associated with an odds ratio of 2.93 CI(0.915,13.1) for subsequent 
response.  Of the 17 patients who did not progress in the trial, only 6/188 (3.2%) had a failure 
to achieve disease control at month four, four died in the induction phase, two were 
withdrawn by their investigator (diagnosis of a new malignancy, occurrence of SAE), three 
withdrew consent, one required additional therapy not permitted in the protocol, and one 
failed screening and did not receive induction therapy.   
 
Biochemical parameters: 
Median B cell count fell from 0.12 x 10
9
/l (12%) (range 0-3.49 (0-46%)) at baseline to 0 x 
10
9
/l (0%) (range 0-1 (0-3%)) at month 4.  There was no difference in median B cell counts 
between responders and non-responders.  There were modest reductions in c-reactive protein 
levels (median 2.65 mg/l (0-165) at baseline; 1.2 mg/l (0-183) at month 4) and erythrocyte 
sedimentation rate (21.5 mm/hour (1-149) to 12.5 mm/hour (2-100)) following treatment with 
glucocorticoids and rituximab.  Serum creatinine remained stable (92.5 µmol/l (37.1-472) at 
baseline and 97.3 µmol/l (42-542) at month 4).  130/188 (69.1%) patients tested positive for 
ANCA at baseline, and 81/188 patients (43.1%) at month 4.  There was a greater proportion 
of PR3-ANCA positive patients who became ANCA negative (53.2% to 33.1%) compared to 
MPO-ANCA patients (14.9% to 12.4%) (Figure 3).  The two individuals who switched from 
being ANCA negative at baseline, to PR3 ANCA positive at month 4 entered remission. 
 
Safety: 
41 serious adverse events (SAEs) occurred in 27 patients, including 13 severe infections (9 
chest, 3 urinary, and 1 gastrointestinal infection) in 7 patients. 5/13 infections occurred within 
4 weeks of the first induction dose of rituximab.  In addition, there were 86 non-severe 
infections in 59 patients (Supplementary Table 2).  51 patients had an IgG level less than 5 
g/l at some point during the induction phase (Table 2).  Four patients (2.1%) died in the 
induction phase; causes of death included: pneumonia [2], cerebrovascular accident [1], and 
active vasculitis [1]. 
 
DISCUSSION: 
These data from the induction phase of the RITAZAREM trial, the largest reported 
prospective cohort of patients with relapsing AAV, demonstrate that rituximab, in 
conjunction with glucocorticoids, is effective at re-inducing remission in patients with AAV 
who have relapsed, regardless of previous therapy. A high proportion of patients (171/188, 
90%) achieved remission by four months, and it is notable that 71% of patients received the 
lower-dose glucocorticoid regimen. Although there are retrospective series, the only previous 
prospective data on induction of remission for this subgroup of patients with ANCA-
associated vasculitis was from the RAVE trial that observed a higher rate of remission in 50 
relapsing patients treated with rituximab when compared to 50 relapsing patients treated with 
cyclophosphamide(7, 11-15). Thus, these data confirm and extend the data on the efficacy of 
rituximab for relapsing GPA/MPA and supports a recommendation of rituximab for this 
indication.   
The higher remission rate found in RITAZAREM versus RAVE may be due in part to the 
different definitions of remission.  In RITAZAREM, remission was defined as a BVAS/WG 
≤ 1 with a prednisolone dose ≤10 mg/day. The RAVE trial observed a lower remission rate of 
64% at 6 months, but required a BVAS/WG of zero and complete glucocorticoid 
withdrawal(7).  The stricter definition of remission in RAVE, together with differences in 
trial design, and the enrollment in RAVE of a more severely affected patient population 
(median BVAS/WG 8.5 (5-13) for patients treated with rituximab), makes direct comparison 
between RITAZAREM and RAVE difficult. In the current study, only 6 of the 17 patients 
who did not achieve remission, (3.2% of the whole study population) clearly represented 
failure of the therapy.  The remainder were withdrawn from the study protocol either due to 
investigator or participant decision (7 patients, 3.7%), or died (4 patients, 2.1%) within the 
induction phase.  In this cohort, no baseline variables studied were predictive of failure of 
treatment response, although the small numbers of non-responders make it difficult for such 
an analysis to be definitive. 
Induction regimens in AAV have been associated with high rates of serious adverse events 
and these are more frequent and problematic than failures to control disease activity, thus 
improvements in the safety of induction regimens are required. In RITAZAREM SAEs 
occurred in 14.3% of patients which is a lower rate than seen in the RITUXVAS trial in 
which 42% of patients treated with rituximab experienced at least one SAE, and the RAVE 
trial in which 22% of patients experienced at least one Grade 3 adverse event(6, 7).   
In the treatment of AAV concomitant use of glucocorticoids is a major contributor to SAEs, 
especially infective risks, and two glucocorticoid regimens were permitted in this study to 
suit physician preference. The choice of glucocorticoid regimen was not randomized, and 
thus may have been subject to bias, so the relative efficacy of these two regimens cannot be 
completely analyzed.  Nonetheless, these two regimens appeared similarly effective with the 
lower-dose approach providing approximately two-thirds of the total oral glucocorticoid 
exposure, and thus reduced dose glucocorticoids can be recommended as a treatment option 
for this indication.  
The key strength of the study lies in the number of patients recruited, making this the largest 
cohort of patients with relapsing AAV to be studied in a clinical trial, facilitating the 
collection of high quality efficacy and safety data on a complex patient population.  This is a 
typical population of patients relapsing with AAV, enriched for patients with PR3 ANCA 
positivity, with median prior disease duration of 5 years, prior exposure to cyclophosphamide 
and/or rituximab in the majority, and a degree of established chronic damage, meaning that 
results are broadly applicable. A potential weakness of this study was the option for 
investigators to choose, rather than randomly assigning the glucocorticoid dosing regimen in 
a blinded manner. Prescribing practices for use of glucocorticoids in AAV vary, necessitating 
a pragmatic approach to trial design. However, investigators were required to select the 
dosing regimen at enrolment, and tapering schedules were standardised.   
Achieving a negative serum ANCA test following induction therapy is associated with a 
lower subsequent risk of relapse in AAV(16,17). In the current study, despite 90% of patients 
achieving remission at month 4, 46% remained positive for serum ANCA at month 4, 
supporting data from the RAVE trial, in which 53% of patients treated with rituximab 
remained positive for ANCA at 6 months(7)  Follow-up in the randomized phase of the 
RITAZAREM trial will provide further insight into the significance of changes in ANCA 
levels.  
These data from the first phase of RITAZAREM demonstrate that rituximab, in conjunction 
with even relatively low doses of glucocorticoids, is highly effective at re-inducing remission 
in patients with AAV who have relapsed, with a safety profile similar to or better than 
previous studies.  
 
  
Table 1: Baseline demographics 
 Total  
(N=188) 
Age, years: median (range)  59 (19-89) 
Male, number (%) 95 (51%) 
Race, number (%) 
- White 
- Asian 
- Hispanic 
- Black 
- Other 
 
168 (89.4%) 
13 (6.9%) 
3 (1.6%) 
1 (0.5%) 
3 (1.6%) 
Disease duration, years: median (range)  5.0 (0.4-34.5) 
Prior treatment with cyclophosphamide 
Number of patients (%)  
Cumulative dose, grams (g): median 
(range) 
 
149 (79.3%) 
9 (0.15-301) 
Prior rituximab therapy 
Number of patients (%) 
Cumulative dose, grams (g): median 
(range)  
 
67 (35.6%) 
3910 (1000-16000) 
Glucocorticoid induction regimen 
1 mg/kg/day starting dose (1A) 
0.5 mg/kg/day starting dose (1B) 
 
54 (28.7) 
134 (71.3) 
ANCA type 
Anti-proteinase 3 
Anti-myeloperoxidase 
 
137 (72.9%) 
51 (27.1%) 
Relapse type upon entry into trial 
Severe 
Non-severe 
 
119 (63.3%) 
69 (36.7%) 
BVAS/WG: median (range) 5 (3-14) 
 
 
 
 
 
 
Table 2: Adverse events according to glucocorticoid induction regimen 
 Total 1A 1B 
Total Number (%) of participants with an SAE 27 (14.3) 10 (18.5) 17 (12.7) 
Total Number (%) of participants with a serious infection 7 (3.7) 0 7 (5.2) 
Total Number (%) of participants with a non-serious 
infection 
59 (31.4) 12 (22.2) 47 (35.1) 
Number (%) of participants with IgG < 5 g/L 51 (27.1) 27 (50.0) 24 (25.4) 
 
1A: higher dose glucocorticoid induction regimen, starting at 1 mg/kg/day (maximum starting 
dose 60 mg/day); 1B: lower dose glucocorticoid induction regimen, starting at 0.5 mg/kg/day 
(maximum starting dose 30 mg/day). 
 
Figure Legends: 
Figure 1: Consort Diagram 
Figure 2: Disease response according to baseline BVAS/WG score 
Figures represent the number of individuals according to disease status.  In addition to those 
displayed on the graph: at month 1.5, two individuals had severe disease, and 4 were 
withdrawn/missing. At month 3, one individual had severe disease and one limited disease.  
At month 4, one individual had severe disease, 3 limited disease and 3 persistent disease.  
Withdrawn/missing includes all participants who did not attend a study visit either due to 
death, withdrawal from trial or a missed visit. 
Figure 3: Change in ANCA status between Month 0 and Month 4 
Only complete cases reported (n=158).  Figures represent the number of individuals 
according to ANCA status.  In addition to those displayed on the graph, two individuals were 
positive for MPO and PR3 ANCA at month 0. 
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Figures represent the number of individuals according to disease status.  In addition to those displayed 
on the graph: at month 1.5, two individuals had severe disease, and 4 were withdrawn/missing. At 
month 3, one individual had severe disease and one limited disease.  At month 4, one individual had 
severe disease, 3 limited disease and 3 persistent disease.  Withdrawn/missing includes all participants 
who did not attend a study visit either due to death, withdrawal from trial or a missed visit. 
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Figure 3: Change in ANCA status between Month 0 and Month 4 
 
Only complete cases reported (n=158).  Figures represent the number of individuals according to 
ANCA status.  In addition to those displayed on the graph, two individuals were positive for MPO and 
PR3 ANCA at month 0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Effect of baseline variables on disease response at 4 months (un 
adjusted regression analysis) 
Variable 
 
Estimate 95% CI P-value 
ANCA status at enrolment (anti-MPO vs. anti-PR3) 
 
1.23 0.412-4.54 0.727 
Type of relapse (non-severe vs. severe) 
 
2.93 0.915-13.1 0.101 
Glucocorticoid induction regimen (1B vs. 1A) 
 
1.04 0.316-2.96 0.948 
BVAS/WG score 
 
0.878 0.712-1.1 0.236 
Ear, nose and throat involvement (No vs. Yes) 
 
0.924 0.327-2.83 0.884 
Renal involvement (No vs. Yes) 
 
1.5 0.534-4.36 0.444 
Age (years) 
 
1.02 0.983-1.05 0.339 
 
1A: higher dose glucocorticoid induction regimen, starting at 1 mg/kg/day (maximum starting 
dose 60 mg/day); 1B: lower dose glucocorticoid induction regimen, starting at 0.5 mg/kg/day 
(maximum starting dose 30 mg/day). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Line listing of severe adverse events 
System Order Class (SOC) Preferred Term (PT) Number 
Cardiac disorders Acute coronary syndrome 1 
 Cardiac arrest 1 
Gastrointestinal disorders Abdominal pain 1 
 Duodenal ulcer 1 
 Gastrointestinal haemorrhage 1 
 Intestinal perforation 1 
Immune system disorders Vasculitis 3 
Infections and infestations Gastroenteritis Escherichia coli 1 
 Pneumonia/respiratory tract infection 9 
 Urinary tract infection 3 
Injury, poisoning, procedural Wound dehiscence 1 
Complications / investigations Medical observation 1 
Malignancy B-cell lymphoma 1 
Nervous system disorders Cerebrovascular accident 1 
Renal and urinary disorders Enterovesical fistula  1 
 Renal impairment 1 
Respiratory, thoracic and mediastinal 
disorders 
Laryngeal stenosis 3 
Surgical and medical procedures Small intestinal resection 1 
Vascular disorders Aortic dissection 1 
 Deep vein thrombosis 5 
 Pulmonary embolism 3 
 
 
 
 
REFERENCES: 
 
1. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic 
autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139-60. 
2. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 
1967;43(1):8-14. 
3. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse 
versus daily oral cyclophosphamide for induction of remission in antineutrophil 
cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 
2009;150(10):670-80. 
4. Wegener's Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy 
for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351-61. 
5. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A 
randomized trial of maintenance therapy for vasculitis associated with antineutrophil 
cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. 
6. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab 
versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 
2010;363(3):211-20. 
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab 
versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 
2010;363(3):221-32. 
8. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab 
versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 
2014;371(19):1771-80. 
9. Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, et al. Rituximab 
versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm 
antibody-associated vasculitis (RITAZAREM): study protocol for a randomized 
controlled trial. Trials. 2017;18(1):112. 
10. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised 
International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis 
Rheum. 2013;65(1):1-11. 
11. Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a 
conventional maintenance agent in relapsing granulomatosis with polyangiitis: A 
retrospective single-center study. Arthritis & rheumatology. 2014. 
12. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A 
multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic 
antibody-associated vasculitis. Arthritis and rheumatism. 2009;60(7):2156-68. 
13. Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P, et al. Rituximab for 
induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). 
Results of a single-center cohort study on 66 patients. Journal of autoimmunity. 
2014;50:135-41. 
14. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, 
et al. Rituximab for remission induction and maintenance in refractory granulomatosis 
with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis and 
rheumatism. 2012;64(11):3770-8. 
15. Walsh M, Merkel PA, Mahr A, Jayne D.  Effects of duration of glucocorticoid therapy on   
relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.  
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1166-73.  
16. McClure ME, Wason J, Gopaluni S, Tieu J, Smith RM, Jayne DR, et al. Evaluation of 
PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. J Clin Rheumatol. 
2019;25(5):217-23. 
17. Sanders JS, Stassen PM, van Rossum AP, Kallenberg CG, Stegeman CA. Risk factors for 
relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: tools for 
treatment decisions? Clin Exp Rheumatol. 2004;22(6 Suppl 36):S94-101. 
 
 
 
